CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress.
Conference Call and Webcast Information:
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies that have the potential to bring meaningful clinical benefits to targeted patient populations.
Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase 2b-ready investigational product for compulsion-related disorders including Tourette’s Syndrome and Prader-Willi Syndrome, into further studies.
For more information, visit www.relmada.com. Follow us on LinkedIn.
Investor Contact:
Brian Ritchie
LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Inquiries:
Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.27 |
| Daily Change: | -0.05 -1.16 |
| Daily Volume: | 1,128,110 |
| Market Cap: | US$313.120M |
November 13, 2025 November 04, 2025 August 07, 2025 May 12, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
